Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04743791 · ClinicalTrials.gov registry record · Phase 4

Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma

A Phase 4 study of Asthma, sponsored by Sally E. Wenzel MD.

Recruiting
Registry status
Phase 4
Development phase
30
Enrollment target
1
Study location

NCT04743791 is a Phase 4 study of Asthma that is actively recruiting participants, run by Sally E. Wenzel MD. The registered enrollment target is 30 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04743791, a Phase 4 study of Asthma, is actively recruiting participants, sponsored by Sally E. Wenzel MD.

RECRUITING
Registry status
Phase 4
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.

Conditions Studied

Interventions

  • OTHER Placebo
  • DRUG Dupilumab

Study Locations (1)

Pennsylvania

  • The University of Pittsburgh Asthma Institute at UPMC - Pittsburgh

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2022-10-17
Est. Completion 2026-09
Phase Phase 4

Sponsor

Sally E. Wenzel MD

3 total trials

What the Registry Record Tells You About NCT04743791

The ClinicalTrials.gov registry entry for NCT04743791 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (98% lower). The listed sponsor is Sally E. Wenzel MD, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04743791 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04743791 about?

NCT04743791 is a clinical study titled "Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma". Single center, randomized, placebo- controlled study to assess change in mucociliary clearance of moderate to severe asthma patients after treatment with dupilumab or placebo.

What is the current status of trial NCT04743791?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2022-10-17. Estimated completion is 2026-09.

What conditions does trial NCT04743791 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT04743791?

The interventions under investigation include: Placebo (OTHER), Dupilumab (DRUG).

Who is sponsoring clinical trial NCT04743791?

This trial is sponsored by Sally E. Wenzel MD, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04743791 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.